vTv Therapeutics (NASDAQ:VTVT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage presently has a $0.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 15.77% from the […]
vTv Therapeutics (NASDAQ:VTVT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday, Zacks.com reports. The firm currently has a $0.50 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 18.32% from the stock’s […]
vTv Therapeutics (NASDAQ:VTVT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, Zacks.com reports. The firm currently has a $0.75 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 17.19% […]